Applicant, as named in the Orange Book
Bristol-Myers
Next listed expiry: Vidaza on 20 May 2029. 4 products with live protection, 2 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Vidaza azacitidine | azacitidine | 050794 | 20 May 2029 | exclusivity |
| Abraxane paclitaxel | paclitaxel | 021660 | 12 Jul 2034 | patent |
| Inrebic fedratinib hydrochloride | fedratinib hydrochloride | 212327 | 24 Sep 2039 | patent, carve-out possible |
| Cobenfy · 3 strengths trospium chloride; xanomeline tartrate | trospium chloride; xanomeline tartrate | 216158 | 29 Oct 2039 | patent |
Recent events
- 25 Oct 2026Istodax · Generic approved 19 Oct 2026
- 25 Oct 2026Thalomid · First generic approved 24 Apr 2026
- 25 Oct 2026Thalomid · Generic approved 24 Apr 2026
Products without listed protection (2)
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Istodax romidepsin | romidepsin | 022393 | open now | no listed protection |
| Thalomid · 4 strengths thalidomide | thalidomide | 020785 | open now | no listed protection |